MDT (multi-disciplinary team) guidance for managing prostate cancer

21. Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation and
ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 1997; 24:
283−291.
22. Gamé X, Vincendeau S, Palascak R, Milcent S, Fournier R, Houlgatte A. Total and free prostatespecific
antigen levels during the first month of acute prostatitis. Eur Urol 2003; 43: 702−705.
23. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen
to enhance differentiation of prostate cancer from benign prostatic disease: A prospective
multicenter clinical trial. JAMA 1998; 279: 1542−1547.
24. Smith DS, Catalona WJ. Rate of change of serum PSA levels as a method for prostate cancer
detection: J Urol 1994; 152: 1163−1167.
25. Gustafsson O, Norming U, Almgard LE, et al. Diagnostic methods in the detection of prostate
cancer: a study of a randomly selected population of 2,400 men. J Urol 1992; 148: 1827−1831.
26. Mettlin C, Murphy GP, Babalan RJ, et al. The results of a five-year early prostate cancer detection
intervention. Cancer 1996; 77: 150−159.
27. Jones WT, Resnick MI. Prostate ultrasound in screening, diagnosis, and staging of prostate cancer.
Prob Urol 1990; 4: 343−357.
28. Ellis WJ, Chetner MP, Preston SD, Brawer MK. Diagnosis of prostatic carcinoma: The yield of serum
prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994;
152(5 I): 1520−1525.
29. National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment. Full
guideline. London, NICE: 2008.
30. Eskicorapci SY, Baydar DE, Akbal C, et al. An extended 10-core transrectal ultrasonography guided
prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 2004; 45: 444−448.
31. Djavan B, Fong YK, Ravery V, et al. Are repeat biopsies required in men with PSA < or =4 ng/ml? A
multiinstitutional prospective European study. Eur Urol 2005; 47: 38−44.
32. Allen DJ, Hindley R, Clovis S, et al. Does body-coil magnetic-resonance imaging have a role in
the preoperative staging of patients with clinically localized prostate cancer? BJU Int 2004; 94:
534−538.
33. Gerber G, Chodak GW. Assessment of value of routine bone scans in patients with newly
diagnosed prostate cancer. Urology 1991; 37: 418−422.
34. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy,
external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate
cancer. JAMA 1998; 280: 969−974.
35. van As NJ, Norman AR, Thomas K, et al. Predicting the probability of deferred radical treatment
for localised prostate cancer managed by active surveillance. Eur Urol 2008; 54: 1297−1305.
36. van den Bergh RC, Roemeling S, Roobol MJ, et al. Outcomes of men with screen-detected prostate
cancer eligible for active surveillance who were managed expectantly. Eur Urol 2008; Sep 17
[epub].
37. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen
screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J
Natl Cancer Inst 2003; 95: 868−878.
38. Selley S, Donovan J, Faulkner A, et al. Diagnosis, management and screening of early localised
prostate cancer. Health Technol Assess 1997; 1: 1−96.
53